Paper Details

  1. Home
  2. Paper Details

[Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation].

Author: DienerHans-Christoph, HohnloserStefan H, VámosMáté

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the benefits of direct oral anticoagulants (DOACs) over vitamin K antagonists for the treatment of atrial fibrillation. DOACs are more effective and have a lower risk of intracerebral bleeding compared to vitamin K antagonists.
Paper Details　
Original Abstract of the Article :
The development of the direct oral anticoagulants (DOACs) represents one of the major breakthroughs in modern medicine over the last decade. Compared to vitamin K antagonists, all DOACs (dabigatran as a thrombin-Inhibitor, rivaroxaban, apixaban and edoxaban as factor Xa inhibitors) are much easier t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0041-102000

データ提供：米国国立医学図書館（NLM）

Direct Oral Anticoagulants: A New Oasis for Stroke Prevention

Stroke is a devastating condition, like a sudden and violent sandstorm in the desert. This study delves into the world of stroke prevention, focusing on the use of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation. DOACs offer a new and promising approach to managing this condition.

DOACs: A Safer and More Effective Approach

The study found that DOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban, are significantly more effective and safer than vitamin K antagonists in preventing stroke. This is like discovering a new oasis in the desert, offering a more reliable and less risky path to protect patients from this potentially life-altering condition. The findings suggest that DOACs should be the preferred choice for stroke prevention in patients with non-valvular atrial fibrillation.

A Clearer Path to Stroke Prevention

This research sheds light on the importance of choosing the right medication for stroke prevention. DOACs offer a significant improvement over traditional treatment options, providing a clearer path to protect patients from this debilitating condition. It's like finding a more direct and safer route through the desert, ensuring a smoother and more secure journey.

Dr.Camel's Conclusion

This study highlights the transformative power of DOACs in stroke prevention, offering a beacon of hope for patients with atrial fibrillation. It's a reminder that progress in medicine is like finding new oases in the vast desert of disease, leading to better outcomes and improved quality of life.

Date :
  1. Date Completed 2015-07-30
  2. Date Revised 2015-05-14
Further Info :

Pubmed ID

25970416

DOI: Digital Object Identifier

10.1055/s-0041-102000

Related Literature

Article Analysis
・Side Effects of edoxaban
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.